Advanced Refractive predicts first-quarter 2007 launch for novel cataract emulsifier:
This article was originally published in Clinica
Advanced Refractive Technologies believes it could be set to file later this year a US marketing application for its next-generation cataract emulsifier. Its Accupulse device is novel in that it combines water-jet and ultrasound technologies, the company claims. Accupulse is to undergo animal studies designed to optimise the final design characteristics of the product and to prepare the device for FDA 510(k) approval. A 510(k) filing could be completed in the fourth quarter of 2006, with approval and initial sales occurring during the first quarter 2007, said Randy Bailey, the San Clemente, California firm's president and CEO. Around 18 million cataract surgeries are forecast for 2007, the company added.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.